Protalix BioTherapeutics, Inc. and partner Chiesi Farmaceutici S.p.A. believe they have the data needed to resubmit the pegylated enzyme replacement therapy (ERT) pegunigalsidase alfa (PRX-102) to the US Food and Drug Administration after receiving a complete response letter last year. The companies announced positive top line results from the Phase III BALANCE trial on 4 April.
The companies believe pegunigalsidase alfa, a plant cell culture-expressed version of the recombinant α-Galactosidase-A enzyme, could offer a superior once-monthly...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)